Ultragenyx Pharmaceutical Inc 公布的最新研究结果显示,其在研疗法取得了重要进展,不仅实现了生物标志物的显著改善,还为患者带来了明确的功能性获益。
Ultragenyx Pharmaceutical Inc 公布的最新研究结果显示,其在研疗法取得了重要进展,不仅实现了生物标志物的显著改善,还为患者带来了明确的功能性获益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.